GH vs NEO
GH: Guardant Health is a precision oncology company transforming cancer care with FDA-approved blood and tissue tests powered by AI analytics that span early detection, treatment selection, and disease monitoring. NEO: Cancer-focused diagnostic laboratory providing specialized oncology and hematologic testing with expert pathologist interpretation across a network of US and UK labs.
Side-by-side fundamentals
| Metric | GH | NEO | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $150.75 | $14.01 | |
| Market cap as of 2026-07-23 | $19.8B | $1.9B | |
| PEG as of 2026-07-23 | -71.05 | -0.71 | GH lower |
| Net margin as of 2026-07-23 | -40.1% | -13.3% | NEO higher |
| Gross margin as of 2026-07-23 | +64.9% | +43.1% | GH higher |
| Operating margin as of 2026-07-23 | -42.7% | -14.3% | NEO higher |
| ROE as of 2026-07-23 | -246.6% | -11.8% | NEO higher |
| ROA as of 2026-07-23 | -26.5% | -7.2% | NEO higher |
| Debt / equity as of 2026-07-23 | 16.78 | 0.41 | NEO lower |
| Revenue growth (YoY) as of 2026-07-23 | +39.6% | +10.9% | GH higher |
| Revenue CAGR (3y) SEC XBRL | +29.8% | n/a | |
| Beta as of 2026-07-23 | 1.63 | 1.79 | |
| 1-year return as of 2026-07-22 close | +225.9% | +118.2% | GH higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.